Prolight Diagnostics

I analysen från Emergers kan man bl.a. läsa att:

• “The arrival of the first of thirty full commercial prototypes marks a pivotal moment”

• ” Prolight achieved several key technical milestones in Q3’24 as the September business review demonstrated cost-efficient, scalable cartridge production, eliminating the need for expensive liquid reagents and enabling multiplex biomarker testing from a single blood drop.”

• “Management and board members fully exercised their warrants, increasing their ownership to 22.8% of total shares—a strong signal of insider confidence in Prolight’s progress and potential.”

 
Läs artikeln här: https://www.emergers.se/prolight-g/